Genome-Wide Growth Factor Discovery in the CNS
DESCRIPTION:We propose to carry out a rapid genome-wide search for new mitogens
and survival factors for stem and precursor cells of the CNS, potentially
doubling or more the number of known CNS mitogenic and survival factors over
the course of two years. To do this, a novel protein expression technology,
called Random Activated Gene Expression (RAGE), will be used. RAGE libraries
containing as few as 5 million individual clones have been shown to be capable
of expressing protein from the vast majority of human genes. By combining the
RAGE protein expression libraries with the cellular assays described herein,
mitogenic and survival factors can be rapidly identified, cloned, and
over-expressed to levels suitable for commercialization (e.g., 250 mg/liter).
In addition to potential direct medical and therapeutic benefits, the discovery
of new proteins with activities in promoting cell survival and division has
considerable benefits on biological research in general. Even the limited
number of growth factors available has provided a central foundation for the
nascent field of stem cell biology in the CNS. Identifying proteins that
further enable regulation of these populations will provide tools that may
greatly extend our ability to achieve such important goals as repair of CNS
PROPOSED COMMERCIAL APPLICATION:
Novel genes and proteins discovered in the present program have several commercial
applications. First, novel genes and/or proteins will be made available to the research
community as a research product. This will occur most likely by licensing research rights
to an established company specializing in the sale and distribution of research reagents.
Second, novel genes and proteins will be investigated as potential therapeutic agents in
established animal models of human disease. Genes and proteins with demonstrated
activity will be further evaluated as drug candidates, and potentially developed clinically.
Typically, an established pharmaceutical partner would be identified to facilitate development
and commercialization of the drug candidate.
Small Business Information at Submission:
Principal Investigator:John J. Harrington
3201 CARNEGIE AVE CLEVELAND, OH 44115
Number of Employees: